Ravi Salgia to Mutation
This is a "connection" page, showing publications Ravi Salgia has written about Mutation.
Connection Strength
4.410
-
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
Score: 0.312
-
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
Score: 0.290
-
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
Score: 0.263
-
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn. 2016 07; 16(7):737-49.
Score: 0.256
-
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
Score: 0.239
-
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
Score: 0.167
-
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
Score: 0.152
-
Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84.
Score: 0.134
-
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
Score: 0.132
-
Targeting c-Kit mutations: basic science to novel therapies. Leuk Res. 2004 May; 28 Suppl 1:S11-20.
Score: 0.111
-
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11).
Score: 0.107
-
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
Score: 0.107
-
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. J Clin Oncol. 2023 02 10; 41(5):1129-1131.
Score: 0.100
-
Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
Score: 0.091
-
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
Score: 0.090
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
Score: 0.088
-
Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
Score: 0.083
-
The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. Bioinformatics. 2019 08 15; 35(16):2738-2748.
Score: 0.080
-
Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43.
Score: 0.077
-
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
Score: 0.072
-
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
Score: 0.070
-
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
Score: 0.068
-
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3.
Score: 0.065
-
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12.
Score: 0.064
-
Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
Score: 0.063
-
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biol Ther. 2016; 17(1):91-103.
Score: 0.062
-
Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. Nanomedicine. 2015 Nov; 11(8):1971-4.
Score: 0.061
-
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
Score: 0.058
-
Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91.
Score: 0.052
-
MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
Score: 0.051
-
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
Score: 0.049
-
Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
Score: 0.045
-
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24.
Score: 0.043
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
Score: 0.043
-
MET receptor tyrosine kinase. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1064-5.
Score: 0.041
-
Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
Score: 0.040
-
Role of c-Met in cancer: emphasis on lung cancer. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S52-8.
Score: 0.039
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.039
-
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 2008 Jun; 7(6):856-63.
Score: 0.036
-
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
Score: 0.036
-
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53.
Score: 0.034
-
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
Score: 0.033
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
Score: 0.029
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26.
Score: 0.029
-
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25.
Score: 0.027
-
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk. J Cancer Res Clin Oncol. 2023 Jul; 149(8):5231-5240.
Score: 0.025
-
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002 Feb; 13(1):41-59.
Score: 0.024
-
The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505.
Score: 0.023
-
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039.
Score: 0.023
-
Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103.
Score: 0.018
-
Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
Score: 0.018
-
Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget. 2017 Jun 27; 8(26):42198-42213.
Score: 0.017
-
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
Score: 0.016
-
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9.
Score: 0.016
-
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
Score: 0.015
-
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
Score: 0.014
-
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
Score: 0.013
-
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
Score: 0.012
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.011
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.011
-
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 2009 Oct 02; 284(40):27524-32.
Score: 0.010
-
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat Clin Pract Oncol. 2006 Jan; 3(1):50-7; quiz 1 p following 57.
Score: 0.008
-
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
Score: 0.005
-
Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 03; 18(22):3343-53.
Score: 0.005